high
Sell
121,117 shares
$662,510
Significance
7/10
CMO Jamil Khurram sold 121,117 shares ($662.5K) in 4 separate transactions at $5.47; 96.4% of holdings liquidated
Jamil Khurram, Chief Medical Officer, executed 4 separate sales totaling 121,117 shares for $662,509.99, reducing his holdings from 125,596 shares to 4,479 shares—a near-complete liquidation representing -96.4% of pre-transaction holdings. The transaction occurs as GALECTIN THERAPEUTICS reports a negative net income of $-8,184,000.00 and faces ongoing unprofitability. The magnitude and concentration of this sale by a senior medical officer warrants investor attention, particularly in a loss-making biotech context where insider equity stakes typically carry significant informational weight.